We report here that treatment with BRAF or MEK inhibitors upregulates CD47 in melanoma cells in vitro and in vivo, and that melanoma cells resistant to BRAF inhibitors are more susceptible to macrophage phagocytosis upon CD47 blockade. This evidence concerns the gene BRAF and melanoma.